Sage Therapeutics, Inc.
SAGE
$7.44
$0.010.14%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 41.24M | 106.40M | 97.24M | 91.06M | 86.46M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 41.24M | 106.40M | 97.24M | 91.06M | 86.46M |
| Cost of Revenue | 246.42M | 276.64M | 318.22M | 351.61M | 371.67M |
| Gross Profit | -205.18M | -170.24M | -220.97M | -260.55M | -285.21M |
| SG&A Expenses | 216.42M | 216.89M | 241.81M | 261.39M | 274.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 451.76M | 478.86M | 546.76M | 599.73M | 632.92M |
| Operating Income | -410.52M | -372.46M | -449.51M | -508.67M | -546.46M |
| Income Before Tax | -400.67M | -337.59M | -445.67M | -503.14M | -541.49M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -400.67 | -337.59 | -445.67 | -503.14 | -541.49 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -400.67M | -337.59M | -445.67M | -503.14M | -541.49M |
| EBIT | -410.52M | -372.46M | -449.51M | -508.67M | -546.46M |
| EBITDA | -409.49M | -371.15M | -448.13M | -507.26M | -545.07M |
| EPS Basic | -6.60 | -5.58 | -7.41 | -8.40 | -9.05 |
| Normalized Basic EPS | -3.90 | -3.49 | -4.29 | -4.90 | -5.31 |
| EPS Diluted | -6.60 | -5.58 | -7.41 | -8.40 | -9.05 |
| Normalized Diluted EPS | -3.90 | -3.49 | -4.29 | -4.90 | -5.31 |
| Average Basic Shares Outstanding | 243.05M | 241.78M | 240.58M | 239.81M | 239.35M |
| Average Diluted Shares Outstanding | 243.05M | 241.78M | 240.58M | 239.81M | 239.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |